LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today...
Imeglimin met its key efficacy endpoint of HbA1c reduction, demonstrating how its unique dual mechanism of action was observed to show added efficacy benefits in combination with existing hypoglycemic agents In particular, Imeglimin was observed to demonstrate...
Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO’s platform for worldwide gene therapy commercialization CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO (NASDAQ: AVRO) (the “Company”), a...
– New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration based on data from phase 1b COSMIC-021 trial –...
Clinical trial application for pivotal JTA-004 Phase III study submitted Start patient enrollment anticipated early 2020 with topline results expected in Q2 2021 BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the...
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints MIN-117 was generally well-tolerated with a safety profile comparable to placebo Company to host conference call at 5:00 p.m. today (dial-in information below) WALTHAM, Mass., Dec. 18,...
Email
Text